Detalhe da pesquisa
1.
A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease.
Am J Hematol
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38562044
2.
Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher disease.
Intern Med J
; 54(3): 398-403, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37493453
3.
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy.
Int J Mol Sci
; 24(7)2023 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37047707
4.
Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.
Int J Mol Sci
; 24(4)2023 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36835356
5.
Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease.
Intern Med J
; 52(5): 872-875, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35538014
6.
Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease.
Int J Mol Sci
; 23(22)2022 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36430458
7.
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Int J Mol Sci
; 23(3)2022 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35163551
8.
A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease-Identifying Those at the Greatest Risk.
Int J Mol Sci
; 23(20)2022 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36293067
9.
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.
Haematologica
; 106(2): 437-445, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001533
10.
Risk of postpartum hemorrhage in multiparous women with Gaucher disease: A call for reconsidering enzyme replacement therapy in all pregnant patients.
J Inherit Metab Dis
; 44(5): 1165-1173, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829536
11.
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Am J Hematol
; 96(5): 545-551, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33606887
12.
Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy.
J Med Genet
; 57(2): 124-131, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31649052
13.
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations.
Int J Mol Sci
; 22(14)2021 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34299318
14.
Gaucher disease, myelodysplastic syndrome and ICUS.
Blood Cells Mol Dis
; 80: 102373, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31718920
15.
Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Blood Cells Mol Dis
; 82: 102418, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32146279
16.
The definition of neuronopathic Gaucher disease.
J Inherit Metab Dis
; 43(5): 1056-1059, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242941
17.
Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.
Int J Mol Sci
; 21(19)2020 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998334
18.
Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease.
Int J Mol Sci
; 21(19)2020 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32987733
19.
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
Blood Cells Mol Dis
; 78: 14-21, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27499018
20.
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Am J Hematol
; 94(1): 29-38, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30264864